Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | F2R | P25116 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16591602 | 0.85 | HSD17B10 (0.41) | HSD17B10LMNASMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL20939157 | 0.84 | PTGES (0.41) | HSD17B10SMN1; SMN2TSHRALDH1A1ITGB3 | |
| SCHEMBL25959561 | 0.82 | HSD17B10 (0.40) | HSD17B10LMNASMN1; SMN2CYP3A4TSHR | |
| SCHEMBL25959855 | 0.82 | HSD17B10 (0.40) | HSD17B10LMNASMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL27105971 | 0.81 | HSD17B10 (0.62) | HSD17B10EPHX2MAPTLMNAHTT | |
| SCHEMBL20381521 | 0.81 | HSD17B10 (0.62) | HSD17B10EPHX2MAPTLMNAHTT | |
| SCHEMBL20939096 | 0.80 | HSD17B10 (0.61) | HSD17B10EPHX2MAPTLMNAHTT | |
| SCHEMBL20381638 | 0.77 | HSD17B10 (0.64) | HSD17B10EPHX2MAPTLMNAHTT | |
| SCHEMBL12197917 | 0.75 | HSD17B10 (0.68) | HSD17B10EPHX2MAPTLMNAHTT | |
| SCHEMBL7750667 | 0.74 | HSD17B10 (0.66) | HSD17B10EPHX2MAPTLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718630-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230135350-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-04 | — | — | US | disclosed |
| US-20210230183-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-07-29 | — | — | US | disclosed |
| US-11008334-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200255446-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135350-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | HSD17B10 3787/4885EPHX2 2775/4885MAPT 3731/4885 |
| US-11718630-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | HSD17B10 3787/4885EPHX2 2775/4885MAPT 3731/4885 |
| US-20210230183-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | HSD17B10 3787/4885EPHX2 2775/4885MAPT 3731/4885 |
| US-20200255446-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | HSD17B10 3787/4885EPHX2 2775/4885MAPT 3731/4885 |
| US-11008334-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | HSD17B10 3787/4885EPHX2 2775/4885MAPT 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.